Innate Pharma Stock Price on November 7, 2024
| IPHA Stock | USD 1.97 0.16 8.84% |
Below is the normalized historical share price chart for Innate Pharma extending back to October 17, 2019. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Innate Pharma stands at 1.97, as last reported on the 28th of March, with the highest price reaching 2.00 and the lowest price hitting 1.92 during the day.
If you're considering investing in Innate Stock, it is important to understand the factors that can impact its price. At this point, Innate Pharma is very risky. Innate Pharma holds Efficiency (Sharpe) Ratio of 0.0276, which attests that the entity had a 0.0276 % return per unit of risk over the last 3 months. We have found twenty-three technical indicators for Innate Pharma, which you can use to evaluate the volatility of the firm. Please check out Innate Pharma's Standard Deviation of 5.04, market risk adjusted performance of (0.02), and Risk Adjusted Performance of 0.0053 to validate if the risk estimate we provide is consistent with the expected return of 0.14%.
At present, Innate Pharma's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Other Stockholder Equity is expected to grow to about 464 M, whereas Common Stock Total Equity is forecasted to decline to about 2.5 M. . The current year's Price Earnings To Growth Ratio is expected to grow to 0.38, whereas Price To Sales Ratio is forecasted to decline to 3.47. Innate Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 17th of October 2019 | 200 Day MA 2.0277 | 50 Day MA 1.9723 | Beta 0.859 |
Innate |
Sharpe Ratio = 0.0276
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | IPHA | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.13 actual daily | 45 55% of assets are more volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Innate Pharma is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Innate Pharma by adding it to a well-diversified portfolio.
Price Book 4.8766 | Enterprise Value Ebitda (6.94) | Price Sales 4.9359 | Shares Float 33.2 M | Wall Street Target Price 8.015 |
Innate Pharma Valuation on November 7, 2024
It is possible to determine the worth of Innate Pharma on a given historical date. On November 7, 2024 Innate was worth 1.82 at the beginning of the trading date compared to the closed value of 1.84. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Innate Pharma stock. Still, in general, we apply an absolute valuation method to find Innate Pharma's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Innate Pharma where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Innate Pharma's related companies.
| Open | High | Low | Close | Volume | |
| 2.06 | 2.06 | 2.06 | 2.06 | 349.00 | |
11/07/2024 | 1.82 | 1.85 | 1.71 | 1.84 | 3,848 |
| 1.57 | 1.87 | 1.57 | 1.84 | 7,075 |
| Backtest Innate Pharma | | | Innate Pharma History | | | Innate Pharma Valuation | Previous | Next |
Innate Pharma Trading Date Momentum on November 7, 2024
| On November 08 2024 Innate Pharma was traded for 1.84 at the closing time. The top price for the day was 1.87 and the lowest listed price was 1.57 . The trading volume for the day was 7.1 K. The trading history from November 8, 2024 did not cause price change. The trading delta at closing time against the current closing price is 21.20% . |
Innate Pharma Fundamentals Correlations and Trends
By evaluating Innate Pharma's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Innate Pharma's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Innate financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Innate Pharma Stock history
Innate Pharma investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Innate is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Innate Pharma will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Innate Pharma stock prices may prove useful in developing a viable investing in Innate Pharma
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 92.5 M | 53.1 M | |
| Net Loss | -52.3 M | -49.7 M |
Innate Pharma Quarterly Net Working Capital |
|
Innate Pharma Stock Technical Analysis
Innate Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Innate Pharma Period Price Range
Low | March 28, 2025
| High |
0.00 | 0.00 |
Innate Pharma cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Innate Pharma March 28, 2025 Market Strength
Market strength indicators help investors to evaluate how Innate Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Innate Pharma shares will generate the highest return on investment. By undertsting and applying Innate Pharma stock market strength indicators, traders can identify Innate Pharma entry and exit signals to maximize returns
Innate Pharma Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Innate Pharma's price direction in advance. Along with the technical and fundamental analysis of Innate Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Innate to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0053 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | 0.1278 | |||
| Treynor Ratio | (0.03) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Innate Stock analysis
When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |